Cargando…

Correction: Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955342/ https://www.ncbi.nlm.nih.gov/pubmed/33565319 http://dx.doi.org/10.1161/JAHA.119.014653

Ejemplares similares

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
por: Rao, Meena P., et al.
Publicado: (2015)

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
por: Pol, Tymon, et al.
Publicado: (2018)

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
por: Halvorsen, Sigrun, et al.
Publicado: (2014)

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
por: Kirchhof, Paulus, et al.
Publicado: (2018)

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
por: Jaspers Focks, Jeroen, et al.
Publicado: (2016)

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2022)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
por: Seeger, Julia, et al.
Publicado: (2020)

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial
por: Hu, Peter T., et al.
Publicado: (2017)

Correction to: Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation
Publicado: (2022)

Atrial Fibrillation and Cryptogenic Thromboembolic Events
por: Henz, Benhur Davi, et al.
Publicado: (2018)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation
por: Deedwania, Prakash, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)

Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
por: Hersi, Ahmad S., et al.
Publicado: (2019)

Correction: IL6 trans-signaling associates with ischemic stroke but not with atrial fibrillation
por: Ziegler, Louise, et al.
Publicado: (2022)

Correction: Measurement of blood pressure in people with atrial fibrillation
por: Clark, Christopher E., et al.
Publicado: (2020)

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
por: Dorian, Paul, et al.
Publicado: (2014)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Impact of dronedarone in atrial fibrillation and flutter on stroke reduction
por: Christiansen, Christine Benn, et al.
Publicado: (2010)

Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial
por: Guimarães, Patricia O., et al.
Publicado: (2019)

Atrial Fibrosis, Ischaemic Stroke and Atrial Fibrillation
por: Mahnkopf, Christian, et al.
Publicado: (2021)

Correction to: MR‑imaging pattern is not a predictor of occult atrial fibrillation in patients with cryptogenic stroke
por: Vollmuth, Christoph, et al.
Publicado: (2020)

Correction to: Plasma Total Homocysteine Level Is Related to Unfavorable Outcomes in Ischemic Stroke With Atrial Fibrillation
Publicado: (2022)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Atrial Fibrillation Related and Unrelated Stroke Recurrence Among Ischemic Stroke Patients With Atrial Fibrillation
por: Kim, Bum Joon, et al.
Publicado: (2021)

Differences in Stroke or Systemic Thromboembolism Readmission Risk After Hospitalization for Atrial Fibrillation and Atrial Flutter
por: Thyagaturu, Harshith S, et al.
Publicado: (2022)

Left Atrial Diameter in the Prediction of Thromboembolic Event and Death in Atrial Fibrillation
por: Krittayaphong, Rungroj, et al.
Publicado: (2022)

A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
por: Pinyol, Carme, et al.
Publicado: (2016)

Correction to: Fine Fibrillatory Wave as a Risk Factor for Heart Failure Events in Patients With Atrial Fibrillation: The Fushimi Atrial Fibrillation (AF) Registry
Publicado: (2022)

Atrial Fibrillation and Cause‐Specific Risks of Pulmonary Embolism and Ischemic Stroke
por: Hald, Erin M., et al.
Publicado: (2018)

Pacemakers as Atrial Fibrillation Detectors: Finding Racial Differences and Opportunities for Preventing Stroke
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d91d4sunlfmdubqlkg2rohgd70